Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Zealand Pharma A/S Stock Up 0.6 %
Shares of ZEAL Stock traded up $0.10 during mid-day trading on Monday, hitting $18.30. 1,662 shares of the stock traded hands, compared to its average volume of 5,408. The stock has a market cap of $851.44 million, a P/E ratio of -5.06 and a beta of 1.49. The stock's fifty day moving average is $14.76 and its two-hundred day moving average is $14.54. Zealand Pharma A/S has a 52-week low of $9.93 and a 52-week high of $34.30. The company has a debt-to-equity ratio of 0.93, a current ratio of 4.79 and a quick ratio of 4.78.
Zealand Pharma A/S (NASDAQ:ZEAL - Get Rating) last released its quarterly earnings results on Thursday, May 12th. The company reported ($0.63) EPS for the quarter, beating the consensus estimate of ($1.01) by $0.38. The business had revenue of $2.27 million during the quarter, compared to analyst estimates of $9.03 million. Zealand Pharma A/S had a negative net margin of 380.22% and a negative return on equity of 89.90%. During the same period in the prior year, the firm posted ($0.94) earnings per share. Equities analysts predict that Zealand Pharma A/S will post -3.53 EPS for the current year.